ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer
09 Mai 2023 - 1:00PM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a
clinical-stage immuno-oncology company developing therapies to
block the CD47 checkpoint mechanism, today announced the initiation
of a Phase 2 investigator-sponsored trial of evorpacept, a next
generation CD47 blocker, in combination with liposomal doxorubicin
and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in
patients with recurrent platinum-resistant ovarian cancer at the
UPMC Hillman Cancer Center.
This is an open-label, single-arm Phase 2 clinical trial
(NCT05467670). The study is being led by Haider Mahdi, M.D.,
M.P.H., Assistant Professor, Department of Obstetrics, Gynecology
and Reproductive Sciences, The University of Pittsburgh and UPMC
Magee-Womens Research Institute, the largest U.S. research
institute dedicated to women’s health research. Merck, known as MSD
outside the United States and Canada, will provide KEYTRUDA to
support this study.
“We are excited to launch this study and to evaluate evorpacept
in this novel therapeutic combination in a difficult-to-treat
population,” said Dr. Mahdi. “Ovarian cancer patients who develop
platinum-resistant disease have poor prognosis, and are in
desperate need for new treatment options that are safe and
effective. From a mechanistic standpoint, CD47 blockade has been
shown to complement chemotherapeutic agents and immune checkpoint
inhibitors. We anticipate that the combination of evorpacept,
liposomal doxorubicin and pembrolizumab may lead to improved
efficacy and a more favorable benefit-risk profile.”
ALX Oncology owns worldwide commercial rights to evorpacept.
About Ovarian Cancer
Ovarian cancer is the fifth leading cause of cancer-related
deaths among women in the United States and eighth worldwide.
According to estimates from the American Cancer Society, more than
19,000 women were diagnosed with ovarian cancer in the United
States and there were nearly 13,000 deaths from ovarian cancer in
2022. Despite recent advances in the therapeutic landscape of newly
diagnosed ovarian cancer, advanced ovarian cancer is still
considered incurable for the majority of patients, and 80% of
patients with advanced ovarian cancer will experience a disease
recurrence.About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage
immuno-oncology company focused on helping patients fight cancer by
developing therapies that block the CD47 checkpoint pathway and
bridge the innate and adaptive immune system. ALX Oncology’s lead
product candidate, evorpacept, is a next generation CD47 blocking
therapeutic that combines a high-affinity CD47 binding domain with
an inactivated, proprietary Fc domain. Evorpacept has demonstrated
promising clinical responses across a range of hematologic and
solid malignancies in combination with a number of leading
anti-cancer agents. ALX Oncology intends to continue clinical
development of evorpacept for the treatment of multiple solid tumor
indications and hematologic malignancies.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. Forward-looking
statements include statements regarding future results of
operations and financial position, business strategy, product
candidates, planned preclinical studies and clinical trials,
results of clinical trials, research and development costs,
regulatory approvals, timing and likelihood of success, plans and
objects of management for future operations, as well as statements
regarding industry trends. Such forward-looking statements are
based on ALX Oncology’s beliefs and assumptions and on information
currently available to it on the date of this press release.
Forward-looking statements may involve known and unknown risks,
uncertainties and other factors that may cause ALX Oncology’s
actual results, performance or achievements to be materially
different from those expressed or implied by the forward-looking
statements. These and other risks are described more fully in ALX
Oncology’s filings with the Securities and Exchange Commission
(“SEC”), including ALX Oncology’s Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q and other documents ALX Oncology
files with the SEC from time to time. Except to the extent required
by law, ALX Oncology undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
ALX Oncology Investor Contact:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Argot Partners
(212)-600-1902
alx@argotpartners.com
ALX Oncology Media Contact:
Karen Sharma
MacDougall
(781) 235-3060
alx@macdougall.bio
ALX Oncology (NASDAQ:ALXO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
ALX Oncology (NASDAQ:ALXO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024